EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus

Felicia C Chow iD, Paddy Kafeero, Maria Nakimbugwe, Anthony Ssemaganda, Colman Tayebwa, Elana Farrell iD, Margaret Wilson iD, Payam Nahid iD, Rada Savic, Fiona Cresswell iD, Freddie M Kibengo iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf089 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Felicia C Chow und 10 weiteren Autor:innen. Beteiligte Einrichtung: Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Linezolid, Tuberculosis, Meningeal, HIV Infections, Antitubercular Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculous meningitis (TBM)–related deaths occur early, often within weeks after treatment initiation. Enhanced treatment early in the disease course with agents that effectively penetrate the central nervous system may improve outcomes in TBM.

Methods

We conducted a phase 2, open-label, randomized trial in Masaka, Uganda, to assess the safety and tolerability of linezolid 1200 mg once daily versus no linezolid with high-dose (35 mg/kg/d) or standard-dose (10 mg/kg/d) rifampin for 4 weeks in participants with definite or suspected TBM. The primary endpoint was any grade ≥3 adverse event during the interventional period. Secondary endpoints included overall survival and functional independence adjusted for TBM disease grade.

Results

We randomized 40 participants (98% with human immunodeficiency virus [HIV]). One-fourth had microbiologically confirmed TBM. Nearly 75% had moderate to severe disease (Medical Research Council grades II and III). No significant difference in grade ≥3 adverse event–­free survival was observed across the 4 treatment arms (P = .18) or by linezolid (P = .97) or rifampin (P = .46) treatment group. More favorable overall survival at 12 and 24 weeks (odds ratio, 0.28 [P = .10] and 0.43 [P = .24], respectively) and functional outcome at 12 and 24 weeks (OR for lower modified Rankin Scale score [ie, less disability], 2.22 [P = .18] and 2.00 [P = .24]) were observed in the linezolid group.

Conclusions

The addition of a short course of linezolid to treat predominantly moderate to severe TBM in adults with HIV did not introduce excess toxicity. Our findings add to growing evidence that linezolid is a safe and acceptable treatment for TBM that merits further investigation in larger multisite trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidTuberculosis, MeningealHIV InfectionsAntitubercular AgentsAcetamidesOxazolidinonesHumansMaleFemaleAdultUgandaMiddle AgedRifampinTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

HIVTuberculous meningitislinezolidsafety and tolerability

Substanzen

LinezolidAntitubercular AgentsRifampinAcetamidesOxazolidinones

Autor:innen und Institutionen

  • Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
  • Department of Medicine (Infectious Diseases), University of California, San Francisco, San Francisco, California, USA.
  • UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.
  • Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
  • Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
  • Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.

ORCID-Profile: Felicia C Chow, Elana Farrell, Margaret Wilson, Payam Nahid, Fiona Cresswell, Freddie M Kibengo

Förderung

  • FIC NIH HHS

Zitieren

APA

Chow, F. C., Kafeero, P., Nakimbugwe, M., Ssemaganda, A., Tayebwa, C., Farrell, E., Wilson, M., Nahid, P., Savic, R., Cresswell, F., & Kibengo, F. M. (2025). Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf089

Vancouver

Chow FC, Kafeero P, Nakimbugwe M, Ssemaganda A, Tayebwa C, Farrell E, et al. Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf089

BibTeX
@article{Chow2025,
  author = {Chow, Felicia C and Kafeero, Paddy and Nakimbugwe, Maria and Ssemaganda, Anthony and Tayebwa, Colman and Farrell, Elana and Wilson, Margaret and Nahid, Payam and Savic, Rada and Cresswell, Fiona and Kibengo, Freddie M},
  title = {Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf089}
}
Kostenlos starten →